INVESTORS

Corporate Governance

Leadership Team and Board of Directors

Our passionate team of entrepreneurial global biotechnology and pharma experts working to deliver on BRIM’s mission.

Leadership Team

Photo of Wayne Liaw Wayne Liaw Sr. Formulation Fellow
Dr. Liaw has more than 30 years of experience in formulation and CMC. He has developed drug formulations in small molecule, big molecule, and peptide. He was responsible for senior management in U.S. companies such as Syntex and Optimer Biotech.
Photo of Wayne Liaw
Wayne Liaw
Sr. Formulation Fellow
Dr. Liaw has more than 30 years of experience in formulation and CMC. He has developed drug formulations in small molecule, big molecule, and peptide. He was responsible for senior management in U.S. companies such as Syntex and Optimer Biotech.
Photo of Chyau Liang Chyau Liang Sr. IP Fellow
Dr. Liang has more than 30 years of experience. He is a senior partner at Osha Liang LLP, US lawyer, patent attorney, Taiwan patent attorney, and he is a former professor at the University of Texas-Houston School of Medicine. He is experienced in international patents, strategy analysis, patent application & litigation, IP management and consultant.
Photo of Chyau Liang
Chyau Liang
Sr. IP Fellow
Dr. Liang has more than 30 years of experience. He is a senior partner at Osha Liang LLP, US lawyer, patent attorney, Taiwan patent attorney, and he is a former professor at the University of Texas-Houston School of Medicine. He is experienced in international patents, strategy analysis, patent application & litigation, IP management and consultant.
Photo of Conrad Tou Conrad Tou Sr. Biostatistic Fellow
Dr. Tou has over 30 years of work experience in biotech and major pharmaceutical companies, such as Sanofi-Synthelabo, Sterling-Winthrop, P&G, and AstraZeneca. He was formerly the associate director of Statistics at AstraZeneca, and has expertise in statistics and data management.
Photo of Conrad Tou
Conrad Tou
Sr. Biostatistic Fellow
Dr. Tou has over 30 years of work experience in biotech and major pharmaceutical companies, such as Sanofi-Synthelabo, Sterling-Winthrop, P&G, and AstraZeneca. He was formerly the associate director of Statistics at AstraZeneca, and has expertise in statistics and data management.
Photo of Carl Alden Carl Alden Sr. Toxicology Fellow
Dr. Alden is a veterinarian by training with more than 40 years of pharmaceutical industry toxicology/pathology experience at companies such as Millennium, Searle, Monsanto, Pharmacia, and Procter & Gamble. He retired as the VP of Toxicology at Millennium Pharmaceuticals (Takeda).
Photo of Carl Alden
Carl Alden
Sr. Toxicology Fellow
Dr. Alden is a veterinarian by training with more than 40 years of pharmaceutical industry toxicology/pathology experience at companies such as Millennium, Searle, Monsanto, Pharmacia, and Procter & Gamble. He retired as the VP of Toxicology at Millennium Pharmaceuticals (Takeda).
Photo of Amanda Yen Amanda Yen VP of Finance Amanda Yen graduated from Chung Yuan Christian University and has over 25 years′ experience in accounting and corporate tax. Before BRIM, she was the Financial Controller of GroupM Limited Taiwan Branch leading 20 direct reports in the accounting department to accomplish all financing and accounting-related reports and tax affairs. Prior to that, she was the Finance and Accounting Director of Lotus Pharmaceutical Co. Ltd. (Alvogen Group), managing financial affairs for a listed Taiwan company and its five global subsidiaries. Previous positions include Accounting Director for TaiGen Biotechnology and Accounting Manager at TNT Express Taiwan Branch.
Photo of Amanda Yen
Amanda Yen
VP of Finance
Amanda Yen graduated from Chung Yuan Christian University and has over 25 years′ experience in accounting and corporate tax. Before BRIM, she was the Financial Controller of GroupM Limited Taiwan Branch leading 20 direct reports in the accounting department to accomplish all financing and accounting-related reports and tax affairs. Prior to that, she was the Finance and Accounting Director of Lotus Pharmaceutical Co. Ltd. (Alvogen Group), managing financial affairs for a listed Taiwan company and its five global subsidiaries. Previous positions include Accounting Director for TaiGen Biotechnology and Accounting Manager at TNT Express Taiwan Branch.
Photo of Yi-Chun Maria Chen, PhD Yi-Chun Maria Chen, PhD VP of Business Development Dr Yi-Chun Maria Chen is a cellular immunologist, specializing in the study of T-cell and B-cell activities. She received her PhD in Biochemistry at Stony Brook University and did post-doctoral research at UCSF and Genentech. Maria returned to Taiwan in 2015 and joined Immunwork, Inc. to help set up their business and fundraising strategies. Since joining BRIM in 2020, she has devoted herself to the development of new drugs and the business development of startup companies.
Photo of Yi-Chun Maria Chen, PhD
Yi-Chun Maria Chen, PhD
VP of Business Development
Dr Yi-Chun Maria Chen is a cellular immunologist, specializing in the study of T-cell and B-cell activities. She received her PhD in Biochemistry at Stony Brook University and did post-doctoral research at UCSF and Genentech. Maria returned to Taiwan in 2015 and joined Immunwork, Inc. to help set up their business and fundraising strategies. Since joining BRIM in 2020, she has devoted herself to the development of new drugs and the business development of startup companies.
Photo of Su Lin, MS Su Lin, MS VP of Operation Development Su Lin gained her Master of Science in Hospital Pharmacy Administration at Temple University, Graduate School of Pharmacy. She has nearly 20 years’ experience in the pharmaceutical industry, specifically in regulatory affairs and labeling, and has worked in global pharma such as Intercept and Regeneron Pharmaceuticals.
Photo of Su Lin, MS
Su Lin, MS
VP of Operation Development
Su Lin gained her Master of Science in Hospital Pharmacy Administration at Temple University, Graduate School of Pharmacy. She has nearly 20 years’ experience in the pharmaceutical industry, specifically in regulatory affairs and labeling, and has worked in global pharma such as Intercept and Regeneron Pharmaceuticals.
Photo of Erin Chang, MS Erin Chang, MS VP of Portfolio Development Erin Chang graduated from the Graduate Institute of Toxicology at the National Taiwan University and has more than 15 years’ of experience in new drug development and project management. She previously worked at TTY Biopharm and Taiwan Liposome Company, where she participated in the discovery and clinical development of biologics, peptides, and special dosage new drugs.
Photo of Erin Chang, MS
Erin Chang, MS
VP of Portfolio Development
Erin Chang graduated from the Graduate Institute of Toxicology at the National Taiwan University and has more than 15 years’ of experience in new drug development and project management. She previously worked at TTY Biopharm and Taiwan Liposome Company, where she participated in the discovery and clinical development of biologics, peptides, and special dosage new drugs.
Photo of Mei-Hui Kuo Mei-Hui Kuo COO Mei-Hui Kuo has over 30 years’ experience in the biotechnology pharmaceutical industry. Her most recent role was COO at Senhwa Biosciences, with previous senior positions including VP of Operations at the Development Center for Biotechnology, Director of New Product Development at TTY Biopharm, Senior VP and Board Member at CDIB Bioscience Venture Management, and Assistant VP in the Life Science Investment Unit of Overseas Business Department at China Development Industrial Bank. Mei-Hui has extensive experience in the operation and management of biotechnology companies and is also very familiar with the domestic and foreign investment environment. Mei-Hui received her MS degree in Plant Pathology and Microbiology from National Taiwan University.
Photo of Mei-Hui Kuo
Mei-Hui Kuo
COO
Mei-Hui Kuo has over 30 years’ experience in the biotechnology pharmaceutical industry. Her most recent role was COO at Senhwa Biosciences, with previous senior positions including VP of Operations at the Development Center for Biotechnology, Director of New Product Development at TTY Biopharm, Senior VP and Board Member at CDIB Bioscience Venture Management, and Assistant VP in the Life Science Investment Unit of Overseas Business Department at China Development Industrial Bank. Mei-Hui has extensive experience in the operation and management of biotechnology companies and is also very familiar with the domestic and foreign investment environment. Mei-Hui received her MS degree in Plant Pathology and Microbiology from National Taiwan University.
Photo of Wen Chyi Shyu, PhD Wen Chyi Shyu, PhD CEO With more than two decades of experience working in the life sciences industry, Wen Chyi Shyu has a unique combination of technical and commercial expertise. She has served in a range of global leadership roles for some of the world′s top pharmaceutical companies, including Bristol Myers Squibb and Takeda Pharmaceutical Company. Her experience in R&D ranges from pre-clinical and clinical drug metabolism to pharmacokinetic drug discovery, drug development, and life cycle management. She has authored over 100 scientific publications, been responsible for more than 100 IND submissions, and led NDA/BLA/MAA/SNDA registrations of more than 15 drugs, including maribavir, dapagliflozin, brentuximab vedotin, and vedolizumab. Wen Chyi brings to BRIM extensive industry experience and a passion for driving drug discovery and development innovation. She is on the leadership team of the Drug Metabolism Technical Group (DMTG) and is on the Steering Committee of the New England Drug Metabolism Discussion Working Group (NEDMDG) to identify and improve the drug discovery process and to shorten study turnaround time. Wen Chyi has also established and led numerous cross-functional teams to effectively integrate metabolism, pharmacokinetics, pharmaceutics, and drug safety into drug discovery and development. She has a passion for training, motivating, and developing research scientists to become successful pharmaceutical executives and has built numerous international and multi-disciplinary teams. Wen Chyi holds a Bachelor of Science from the School of Pharmacy at Taipei Medical College and a PhD from the College of Pharmacy at the University of Connecticut, USA. She is also a Post-Doctoral Fellow at the University of Florida.
Photo of Wen Chyi Shyu, PhD
Wen Chyi Shyu, PhD
CEO
With more than two decades of experience working in the life sciences industry, Wen Chyi Shyu has a unique combination of technical and commercial expertise. She has served in a range of global leadership roles for some of the world′s top pharmaceutical companies, including Bristol Myers Squibb and Takeda Pharmaceutical Company. Her experience in R&D ranges from pre-clinical and clinical drug metabolism to pharmacokinetic drug discovery, drug development, and life cycle management. She has authored over 100 scientific publications, been responsible for more than 100 IND submissions, and led NDA/BLA/MAA/SNDA registrations of more than 15 drugs, including maribavir, dapagliflozin, brentuximab vedotin, and vedolizumab. Wen Chyi brings to BRIM extensive industry experience and a passion for driving drug discovery and development innovation. She is on the leadership team of the Drug Metabolism Technical Group (DMTG) and is on the Steering Committee of the New England Drug Metabolism Discussion Working Group (NEDMDG) to identify and improve the drug discovery process and to shorten study turnaround time. Wen Chyi has also established and led numerous cross-functional teams to effectively integrate metabolism, pharmacokinetics, pharmaceutics, and drug safety into drug discovery and development. She has a passion for training, motivating, and developing research scientists to become successful pharmaceutical executives and has built numerous international and multi-disciplinary teams. Wen Chyi holds a Bachelor of Science from the School of Pharmacy at Taipei Medical College and a PhD from the College of Pharmacy at the University of Connecticut, USA. She is also a Post-Doctoral Fellow at the University of Florida.
Photo of James Cheng, JD James Cheng, JD Mr James Cheng is a partner with Tsar & Tsai Law Firm and is both a litigator and a transaction attorney. His areas of specialty include corporate law, insurance, M&A, capital markets, cross-border transactions, BOT projects, and government procurement. On the litigation side, James has assisted numerous high-tech companies on intellectual property disputes, directors of various companies on allegations of breach of trust and breach of fiduciary duty, contractors and construction consulting firms on construction defect cases, and companies having disputes relating to government projects. On the transaction side, James is involved in numerous high-profile cross-border M&As by assisting the client in deal structure, contract negotiation, syndication loan documentation, and post-closing restructure. As an insurance law expert, James also represents multiple insurance businesses in Taiwan on insurance business regulatory compliance matters and claim disputes.
Photo of James Cheng, JD
James Cheng, JD
Mr James Cheng is a partner with Tsar & Tsai Law Firm and is both a litigator and a transaction attorney. His areas of specialty include corporate law, insurance, M&A, capital markets, cross-border transactions, BOT projects, and government procurement. On the litigation side, James has assisted numerous high-tech companies on intellectual property disputes, directors of various companies on allegations of breach of trust and breach of fiduciary duty, contractors and construction consulting firms on construction defect cases, and companies having disputes relating to government projects. On the transaction side, James is involved in numerous high-profile cross-border M&As by assisting the client in deal structure, contract negotiation, syndication loan documentation, and post-closing restructure. As an insurance law expert, James also represents multiple insurance businesses in Taiwan on insurance business regulatory compliance matters and claim disputes.
Photo of Howard Kuo, MBA Howard Kuo, MBA Mr Howard Kuo currently serves on the board of directors in many public and private companies in Taiwan. After retiring from his role as Deputy Chairman of PwC Taiwan and as a lead accountant for Family Business Inheritance and Personal Assets and Tax Management, he continued to teach in the universities and provide guidance to startups. He has over 35 years of experience in accounting and extensive expertise in tax affairs and corporate cross-border investment structure and planning. Howard holds an MBA from the Executive MBA Program of National Taiwan University.
Photo of Howard Kuo, MBA
Howard Kuo, MBA
Mr Howard Kuo currently serves on the board of directors in many public and private companies in Taiwan. After retiring from his role as Deputy Chairman of PwC Taiwan and as a lead accountant for Family Business Inheritance and Personal Assets and Tax Management, he continued to teach in the universities and provide guidance to startups. He has over 35 years of experience in accounting and extensive expertise in tax affairs and corporate cross-border investment structure and planning. Howard holds an MBA from the Executive MBA Program of National Taiwan University.
Johnsee Lee, Ph.D., MBA Dr. Johnsee Lee is the founder, President, and CEO of Personal Genomics, Inc., and has held various technical and managerial positions at Argonne National Laboratories, Johnson Matthey Inc., and Industrial Technology Research Institute (ITRI). Johnsee has many years of hands-on experience in both frontier technology research and industrial commercialization. He received a Ph.D. from the Illinois Institute of Technology, an MBA from the University of Chicago, and is a graduate of Harvard Business School’s Advanced Management Program. After joining ITRI, Johnsee worked his way up from a lab manager to become President of the Institute and played a key leadership role in the development of Taiwan′s world-class high-tech industry. He was the first Director and founder of the Biomedical Engineering Center at ITRI, with expertise covering chemical, biochemical, and molecular technologies. Johnsee is specialized in multidisciplinary technology integration and has successfully led the exploratory research team to develop and commercialize novel technologies for healthcare applications. During his tenure as the President of ITRI, he has created 16 high-tech start-ups and actively supported them with the institute’s incubation and venture programs. Johnsee has published many journal papers and patents. He is an Adjunct Professor at Taipei Medical University, Chairman of the Development Center for Biotechnology in Taiwan, and Director of the Board of Taiwan Semiconductor Manufacturing Co. (TSMC). He is also a recipient of the National Engineering Medal, Economics Contribution Award, and Innovation Leadership Award by Global Views Magazine.
Photo of Johnsee Lee, Ph.D., MBA
Johnsee Lee, Ph.D., MBA
Dr. Johnsee Lee is the founder, President, and CEO of Personal Genomics, Inc., and has held various technical and managerial positions at Argonne National Laboratories, Johnson Matthey Inc., and Industrial Technology Research Institute (ITRI). Johnsee has many years of hands-on experience in both frontier technology research and industrial commercialization. He received a Ph.D. from the Illinois Institute of Technology, an MBA from the University of Chicago, and is a graduate of Harvard Business School’s Advanced Management Program. After joining ITRI, Johnsee worked his way up from a lab manager to become President of the Institute and played a key leadership role in the development of Taiwan′s world-class high-tech industry. He was the first Director and founder of the Biomedical Engineering Center at ITRI, with expertise covering chemical, biochemical, and molecular technologies. Johnsee is specialized in multidisciplinary technology integration and has successfully led the exploratory research team to develop and commercialize novel technologies for healthcare applications. During his tenure as the President of ITRI, he has created 16 high-tech start-ups and actively supported them with the institute’s incubation and venture programs. Johnsee has published many journal papers and patents. He is an Adjunct Professor at Taipei Medical University, Chairman of the Development Center for Biotechnology in Taiwan, and Director of the Board of Taiwan Semiconductor Manufacturing Co. (TSMC). He is also a recipient of the National Engineering Medal, Economics Contribution Award, and Innovation Leadership Award by Global Views Magazine.
Affinity Capital Affinity Capital′s Great Health Fund No. 1 focuses on investing in Taiwan’s life science and health industries. The members of the management team are all senior experts with extensive experience in life sciences, capital markets, investment, mergers and acquisitions, and post-investment management, as well as profound capabilities in business operations.
Photo of Affinity Capital
Affinity Capital
Affinity Capital′s Great Health Fund No. 1 focuses on investing in Taiwan’s life science and health industries. The members of the management team are all senior experts with extensive experience in life sciences, capital markets, investment, mergers and acquisitions, and post-investment management, as well as profound capabilities in business operations.
CIDC Consultants Li-teh Hsu, the chairman of China Investment & Development (CIDC), brought together funding, professional expertise, and human resources from large companies in both Taiwan and Canada to implement investment plans benefiting both investors and the broader economy in Taiwan. He established China Investment & Development Company, Limited with a capital of NT$1.6 billion and a mission encompassing production, trade, services, and investment in technology businesses. Over the past 14 years, CIDC Consultants has invested in 220 domestic and foreign companies, deploying more than NT$10 billion in investments through its three investment vehicles. Members of its investment team have served on the board of directors or board of supervisors of 65 companies. Currently, CIDC Consultants manages three investment funds, with assets under its management totaling NT$6.3 billion. In the past six years, CIDC Consultants has generated capital gains that have exceeded NT$4 billion, an outstanding record in capital management.
Photo of CIDC Consultants
CIDC Consultants
Li-teh Hsu, the chairman of China Investment & Development (CIDC), brought together funding, professional expertise, and human resources from large companies in both Taiwan and Canada to implement investment plans benefiting both investors and the broader economy in Taiwan. He established China Investment & Development Company, Limited with a capital of NT$1.6 billion and a mission encompassing production, trade, services, and investment in technology businesses. Over the past 14 years, CIDC Consultants has invested in 220 domestic and foreign companies, deploying more than NT$10 billion in investments through its three investment vehicles. Members of its investment team have served on the board of directors or board of supervisors of 65 companies. Currently, CIDC Consultants manages three investment funds, with assets under its management totaling NT$6.3 billion. In the past six years, CIDC Consultants has generated capital gains that have exceeded NT$4 billion, an outstanding record in capital management.
Audrey Tseng, MBA Audrey is an advisory member of the Bio Taiwan Committee (BTC), Vice Chairperson of the Taiwan Bio Industry organization, and an Adjunct Professor at National Yang Ming Chiao Tung University. Audrey recently retired from serving as the Deputy Chairman of PwC Taiwan, Assurance Leader, and Bio-Industry Development Committee Leader. She has over 35 years of experience in accounting and sophisticated expertise in assisting biotech industry development and business strategies. Audrey holds an MBA from the Executive MBA Program of Fudan University and National Taiwan University, and a Master of Commerce from the Department of Accounting at National Chengchi University.
Photo of Audrey Tseng, MBA
Audrey Tseng, MBA
Audrey is an advisory member of the Bio Taiwan Committee (BTC), Vice Chairperson of the Taiwan Bio Industry organization, and an Adjunct Professor at National Yang Ming Chiao Tung University. Audrey recently retired from serving as the Deputy Chairman of PwC Taiwan, Assurance Leader, and Bio-Industry Development Committee Leader. She has over 35 years of experience in accounting and sophisticated expertise in assisting biotech industry development and business strategies. Audrey holds an MBA from the Executive MBA Program of Fudan University and National Taiwan University, and a Master of Commerce from the Department of Accounting at National Chengchi University.
Photo of Andrew Lin, MBA Andrew Lin, MBA Chairman of the Board Andrew Lin is the Chairman of TaiRx, Inc. and Nuwa Healthcare. He also serves on the Independent Board of Directors for Fubon Insurance, and is the co-founder of Affinity Capitals. Before joining TaiRx, Andrew was Chairman of Lotus Pharmaceutical, the largest generic drug company listed on the Taiwan Stock Exchange, having previously been CEO of Hasumi Biotechnology International, a global leader in cancer vaccines and immunotherapy. Prior to his biotech career, Andrew’s most recent positions were Chief Strategy Officer for Chicony Electronics/Clevo Group, Managing Director with Macquarie Capital, and Chief Financial Officer for Lite-On Technology Group, a US$10 billion technology giant, headquartered in Taiwan. Andrew has also previously served as Chief Investment Officer for ABN AMRO Asset Management Taiwan, managing their US$4 billion investment portfolio, and Head of Asia Pacific Technology Research for JP Morgan Securities. Additional experience includes management consultancy at McKinsey & Company and Booz Allen Hamilton, as well as R&D roles at AT&T Bell Laboratories, Prime Computer, and Digital Equipment Corporation. Andrew received his MBA degree from The University of Chicago, Graduate School of Business after graduating with an MS degree in electrical and computer engineering from the University of Massachusetts at Amherst.
Photo of Andrew Lin, MBA
Andrew Lin, MBA
Chairman of the Board
Andrew Lin is the Chairman of TaiRx, Inc. and Nuwa Healthcare. He also serves on the Independent Board of Directors for Fubon Insurance, and is the co-founder of Affinity Capitals. Before joining TaiRx, Andrew was Chairman of Lotus Pharmaceutical, the largest generic drug company listed on the Taiwan Stock Exchange, having previously been CEO of Hasumi Biotechnology International, a global leader in cancer vaccines and immunotherapy. Prior to his biotech career, Andrew’s most recent positions were Chief Strategy Officer for Chicony Electronics/Clevo Group, Managing Director with Macquarie Capital, and Chief Financial Officer for Lite-On Technology Group, a US$10 billion technology giant, headquartered in Taiwan. Andrew has also previously served as Chief Investment Officer for ABN AMRO Asset Management Taiwan, managing their US$4 billion investment portfolio, and Head of Asia Pacific Technology Research for JP Morgan Securities. Additional experience includes management consultancy at McKinsey & Company and Booz Allen Hamilton, as well as R&D roles at AT&T Bell Laboratories, Prime Computer, and Digital Equipment Corporation. Andrew received his MBA degree from The University of Chicago, Graduate School of Business after graduating with an MS degree in electrical and computer engineering from the University of Massachusetts at Amherst.
Photo of Shi, Dakun (Daniel) Shi, Dakun (Daniel) Independent Director Mr. Shi, Dakun has more than 40 years of experience in the strategy and operation of large multinational companies and small and medium-sized enterprises. Since 2002, Mr. Shi has been focusing on high-efficiency organizational development, talent cultivation, and executive coaching. Mr. Shi won the China Management Talent Award in 2007 and the World Outstanding Chinese Award in 2008.
Photo of Shi, Dakun (Daniel)
Shi, Dakun (Daniel)
Independent Director
Mr. Shi, Dakun has more than 40 years of experience in the strategy and operation of large multinational companies and small and medium-sized enterprises. Since 2002, Mr. Shi has been focusing on high-efficiency organizational development, talent cultivation, and executive coaching. Mr. Shi won the China Management Talent Award in 2007 and the World Outstanding Chinese Award in 2008.
Photo of Lin, Xiulian (Pearl) Lin, Xiulian (Pearl) Independent Director Accountant Lin, Xiulian specializes in financial planning, tax accounting and auditing, real estate valuation, asset allocation planning, corporate equity, and intangible asset evaluation.
Photo of Lin, Xiulian (Pearl)
Lin, Xiulian (Pearl)
Independent Director
Accountant Lin, Xiulian specializes in financial planning, tax accounting and auditing, real estate valuation, asset allocation planning, corporate equity, and intangible asset evaluation.
Photo of Zeng Huijin (Audrey) Zeng Huijin (Audrey) Director

Audrey has worked in the accounting field for 35 years. She was the certified public accountant of many public companies such as Delta Electronics, Asus, WPG Holdings, etc. She is experienced in the capital market, international financing, tax planning, M&A, corporate governance, industrial development, and managerial strategy. Audrey has supported the IPO of countless biotech companies.

Photo of Zeng Huijin (Audrey)
Zeng Huijin (Audrey)
Director

Audrey has worked in the accounting field for 35 years. She was the certified public accountant of many public companies such as Delta Electronics, Asus, WPG Holdings, etc. She is experienced in the capital market, international financing, tax planning, M&A, corporate governance, industrial development, and managerial strategy. Audrey has supported the IPO of countless biotech companies.

Photo of Hu, Dexing (Philip) Hu, Dexing (Philip) Director Mr. Hu Dexing is known as the “Investment Talent” in Taiwan’s financial industry; he was the managing director of JP Morgan Asset Management and was responsible for banking and securities industry research, funds, insurance and other financial management products, management, and marketing in Fubon Group. He has rich experience in wealth management, asset management, entrepreneurial mentor and various investments, and has achieved success in product innovation, organizational change and leadership.
Photo of Hu, Dexing (Philip)
Hu, Dexing (Philip)
Director
Mr. Hu Dexing is known as the “Investment Talent” in Taiwan’s financial industry; he was the managing director of JP Morgan Asset Management and was responsible for banking and securities industry research, funds, insurance and other financial management products, management, and marketing in Fubon Group. He has rich experience in wealth management, asset management, entrepreneurial mentor and various investments, and has achieved success in product innovation, organizational change and leadership.
Top Taiwan Venture Directors Top Taiwan Venture is the largest leading venture capital management team in Taiwan. It has invested in Dr. Jang and Dr. Lee to start a business since BRIM’s A-round fundraising, supported the Company’s development along the way, and given the team capital market advice. The main investors of the venture capital funds managed by Top Taiwan Venture include 14 large insurance companies and 11 large comprehensive securities companies in Taiwan, ranking first in Taiwan.
Photo of Top Taiwan Venture
Top Taiwan Venture
Directors
Top Taiwan Venture is the largest leading venture capital management team in Taiwan. It has invested in Dr. Jang and Dr. Lee to start a business since BRIM’s A-round fundraising, supported the Company’s development along the way, and given the team capital market advice. The main investors of the venture capital funds managed by Top Taiwan Venture include 14 large insurance companies and 11 large comprehensive securities companies in Taiwan, ranking first in Taiwan.
Photo of Haishan Jang, PhD Haishan Jang, PhD Vice Chairman, CGS (Chief Global Strategist) of BRIM Dr Haishan Jang has over 30 years of experience in the pharmaceutical industry. Prior to forming BRIM, she worked at Sterling Winthrop (Kodak), Sanofi, DuPont, and Centocor (J&J), where she was the Senior Director of Biologics Clinical Pharmacology. Haishan’s extensive experience across the entire drug discovery process, from research through to clinical translation and commercial development, has given her the unique ability to understand the driving factors needed across all parts of a business to deliver world-class, life-changing innovation. Driven by her own need for continued learning, Haishan is passionate about developing and supporting young scientists in Taiwan – driving BRIM′s corporate mission to inspire and nurture the next generation of biotech entrepreneurs and innovators to bring sustainable and affordable healthcare to everyone. Haishan has a PhD in Physical Chemistry and an MBA from Temple University, Pennsylvania.
Photo of Haishan Jang, PhD
Haishan Jang, PhD
Vice Chairman, CGS (Chief Global Strategist) of BRIM
Dr Haishan Jang has over 30 years of experience in the pharmaceutical industry. Prior to forming BRIM, she worked at Sterling Winthrop (Kodak), Sanofi, DuPont, and Centocor (J&J), where she was the Senior Director of Biologics Clinical Pharmacology. Haishan’s extensive experience across the entire drug discovery process, from research through to clinical translation and commercial development, has given her the unique ability to understand the driving factors needed across all parts of a business to deliver world-class, life-changing innovation. Driven by her own need for continued learning, Haishan is passionate about developing and supporting young scientists in Taiwan – driving BRIM′s corporate mission to inspire and nurture the next generation of biotech entrepreneurs and innovators to bring sustainable and affordable healthcare to everyone. Haishan has a PhD in Physical Chemistry and an MBA from Temple University, Pennsylvania.
Photo of Isaiah Capital LLC Isaiah Capital LLC Isaiah Capital specializes in the investment and management of innovative technology industries. One of its representatives was the director of BRIM′s A round of fundraising and also invested in BRIM′s B and C rounds of fundraising. In the D round of fundraising, Isaiah Capital coordinated with BRIM to bring investors with more international capital market experience to help BRIM execute IPO strategies and establish international financial planning. Isaiah Capital also joined the most recent Series E round to continue to support BRIM′s growth.
Photo of Isaiah Capital LLC
Isaiah Capital LLC
Isaiah Capital specializes in the investment and management of innovative technology industries. One of its representatives was the director of BRIM′s A round of fundraising and also invested in BRIM′s B and C rounds of fundraising. In the D round of fundraising, Isaiah Capital coordinated with BRIM to bring investors with more international capital market experience to help BRIM execute IPO strategies and establish international financial planning. Isaiah Capital also joined the most recent Series E round to continue to support BRIM′s growth.
Photo of Frank W. Lee Frank W. Lee CSO Dr Frank Lee has over four decades of R&D experience working in drug metabolism and pharmacokinetics (DMPK), drug candidate selection, and first-in-human (FIH) clinical trials strategy for some of the world′s largest pharmaceutical companies, including Syntex, Glaxo, Dupont, Millennium, and Takeda. During his career, Frank has participated in the development of several brand-name drugs such as Naprosyn®, Anaprox®, and Ticlid®. Prior to his retirement in 2012, he held the position of VP of DMPK at Takeda, where he oversaw DMPK and participated in the drug candidate selection and FIH strategy. In addition to holding a Board position at BRIM, Frank sits on the board at Foresee Pharmaceuticals in Taiwan. He is passionate about putting Taiwanese biotech companies on the global stage and believes that pioneering research and advanced technologies are the keys to discovering new medicines for urgent, unmet medical needs. Frank has a PhD in Medicinal Chemistry from the University of California, San Francisco.
Photo of Frank W. Lee
Frank W. Lee
CSO
Dr Frank Lee has over four decades of R&D experience working in drug metabolism and pharmacokinetics (DMPK), drug candidate selection, and first-in-human (FIH) clinical trials strategy for some of the world′s largest pharmaceutical companies, including Syntex, Glaxo, Dupont, Millennium, and Takeda. During his career, Frank has participated in the development of several brand-name drugs such as Naprosyn®, Anaprox®, and Ticlid®. Prior to his retirement in 2012, he held the position of VP of DMPK at Takeda, where he oversaw DMPK and participated in the drug candidate selection and FIH strategy. In addition to holding a Board position at BRIM, Frank sits on the board at Foresee Pharmaceuticals in Taiwan. He is passionate about putting Taiwanese biotech companies on the global stage and believes that pioneering research and advanced technologies are the keys to discovering new medicines for urgent, unmet medical needs. Frank has a PhD in Medicinal Chemistry from the University of California, San Francisco.
Photo of Haishan Jang Haishan Jang Chairwoman and Chief Executive Officer Orci varius natoque penatibus et magnis dis parturient montes, nascetur ridiculus mus. Nullam imperdiet diam nibh, eget faucibus risus imperdiet sit amet. Praesent ut tortor efficitur, auctor urna non, interdum ipsum. Fusce pellentesque tincidunt nunc, vitae tincidunt diam vestibulum nec. Vivamus sagittis, est ac tempor pharetra, est lorem sollicitudin dui, congue fermentum diam augue volutpat nulla. Duis fringilla accumsan augue, nec tincidunt nisl. Proin sed sem nec leo porta ultricies at consequat quam. Phasellus sit amet ipsum magna. Donec facilisis massa vitae leo varius semper. Interdum et malesuada fames ac ante ipsum primis in faucibus.
Photo of Haishan Jang
Haishan Jang
Chairwoman and Chief Executive Officer
Orci varius natoque penatibus et magnis dis parturient montes, nascetur ridiculus mus. Nullam imperdiet diam nibh, eget faucibus risus imperdiet sit amet. Praesent ut tortor efficitur, auctor urna non, interdum ipsum. Fusce pellentesque tincidunt nunc, vitae tincidunt diam vestibulum nec. Vivamus sagittis, est ac tempor pharetra, est lorem sollicitudin dui, congue fermentum diam augue volutpat nulla. Duis fringilla accumsan augue, nec tincidunt nisl. Proin sed sem nec leo porta ultricies at consequat quam. Phasellus sit amet ipsum magna. Donec facilisis massa vitae leo varius semper. Interdum et malesuada fames ac ante ipsum primis in faucibus.

Interested in becoming an investor in BRIM Biotechnology?

Please get in touch using our email or form found on our contact page

Download BRIM's Corporate Overview

This site is registered on wpml.org as a development site.